Trial Profile
MoTriColor: Phase I/II Study With Galunisertib (LY2157299) Combined With Capecitabine in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and an Activated TGF-beta Signature
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Galunisertib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EORTC1615
- 29 Aug 2019 This trial has been discontinued in Belgium and Italy according to European clinical trials database record.
- 22 Jul 2019 Planned initiation date changed from 1 Apr 2018 to 24 Aug 2018.
- 22 Jul 2019 Status changed from recruiting to withdrawn prior to enrolment.